UK losing out on global R&D investment, says ABPI report

The UK’s leading role as a drug discovery pioneer could be under threat as the country begins to lose out on global investment, according to a report by the Association of the British Pharmaceutical Industry (ABPI).

The report, The Changing UK Drug Discovery Landscape, produced by consultants TBR and CBSL, was launched at a FORUM event hosted by the Academy of Medical Sciences.

“What we urgently need right now is a great deal more funding available to support crossing the so-called valley of death between progress in early drug discovery in academia and commercial development to roll out new treatments.”